{"title":"A Polygenic Risk Score in Practice.","authors":"David J Hunter","doi":"10.1056/nejme2503155","DOIUrl":"https://doi.org/10.1056/nejme2503155","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"5 1","pages":"1444-1446"},"PeriodicalIF":158.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143822576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas M Maddox,Peter Embí,Jackie Gerhart,Jennifer Goldsack,Ravi B Parikh,Troy C Sarich
{"title":"Generative AI in Medicine - Evaluating Progress and Challenges.","authors":"Thomas M Maddox,Peter Embí,Jackie Gerhart,Jennifer Goldsack,Ravi B Parikh,Troy C Sarich","doi":"10.1056/nejmsb2503956","DOIUrl":"https://doi.org/10.1056/nejmsb2503956","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"37 1","pages":""},"PeriodicalIF":158.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143822479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Extrachromosomal DNA - Amping Up Cancer.","authors":"Lillian L Siu,Trevor J Pugh","doi":"10.1056/nejmcibr2415911","DOIUrl":"https://doi.org/10.1056/nejmcibr2415911","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"39 1","pages":"1447-1450"},"PeriodicalIF":158.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143822573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jana K McHugh,Elizabeth K Bancroft,Edward Saunders,Mark N Brook,Eva McGrowder,Sarah Wakerell,Denzil James,Reshma Rageevakumar,Barbara Benton,Natalie Taylor,Kathryn Myhill,Matthew Hogben,Netty Kinsella,Aslam A Sohaib,Declan Cahill,Stephen Hazell,Samuel J Withey,Naami Mcaddy,Elizabeth C Page,Andrea Osborne,Sarah Benafif,Ann-Britt Jones,Dhruv Patel,Dean Y Huang,Kaljit Kaur,Bradley Russell,Ray Nicholson,Fionnuala Croft,Justyna Sobczak,Claire McNally,Fiona Mutch,Samantha Bennett,Lenita Kingston,Questa Karlsson,Tokhir Dadaev,Sibel Saya,Susan Merson,Angela Wood,Nening Dennis,Nafisa Hussain,Alison Thwaites,Syed Hussain,Imran Rafi,Michelle Ferris,Pardeep Kumar,Nicholas D James,Nora Pashayan,Zsofia Kote-Jarai,Rosalind A Eeles,
{"title":"Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.","authors":"Jana K McHugh,Elizabeth K Bancroft,Edward Saunders,Mark N Brook,Eva McGrowder,Sarah Wakerell,Denzil James,Reshma Rageevakumar,Barbara Benton,Natalie Taylor,Kathryn Myhill,Matthew Hogben,Netty Kinsella,Aslam A Sohaib,Declan Cahill,Stephen Hazell,Samuel J Withey,Naami Mcaddy,Elizabeth C Page,Andrea Osborne,Sarah Benafif,Ann-Britt Jones,Dhruv Patel,Dean Y Huang,Kaljit Kaur,Bradley Russell,Ray Nicholson,Fionnuala Croft,Justyna Sobczak,Claire McNally,Fiona Mutch,Samantha Bennett,Lenita Kingston,Questa Karlsson,Tokhir Dadaev,Sibel Saya,Susan Merson,Angela Wood,Nening Dennis,Nafisa Hussain,Alison Thwaites,Syed Hussain,Imran Rafi,Michelle Ferris,Pardeep Kumar,Nicholas D James,Nora Pashayan,Zsofia Kote-Jarai,Rosalind A Eeles,","doi":"10.1056/nejmoa2407934","DOIUrl":"https://doi.org/10.1056/nejmoa2407934","url":null,"abstract":"BACKGROUNDThe incidence of prostate cancer is increasing. Screening with an assay of prostate-specific antigen (PSA) has a high rate for false positive results. Genomewide association studies have identified common germline variants in persons with prostate cancer, which can be used to calculate a polygenic risk score associated with risk of prostate cancer.METHODSWe recruited persons 55 to 69 years of age from primary care centers in the United Kingdom. Using germline DNA extracted from saliva, we derived polygenic risk scores from 130 variants known to be associated with an increased risk of prostate cancer. Participants with a polygenic risk score in the 90th percentile or higher were invited to undergo prostate cancer screening with multiparametric magnetic resonance imaging (MRI) and transperineal biopsy, irrespective of PSA level.RESULTSAmong 40,292 persons invited to participate, 8953 (22.2%) expressed interest in participating and 6393 had their polygenic risk score calculated; 745 (11.7%) had a polygenic risk score in the 90th percentile or higher and were invited to undergo screening. Of these 745 participants, 468 (62.8%) underwent MRI and prostate biopsy; prostate cancer was detected in 187 participants (40.0%). The median age at diagnosis was 64 years (range, 57 to 73). Of the 187 participants with cancer, 103 (55.1%) had prostate cancer classified as intermediate or higher risk according to the 2024 National Comprehensive Cancer Network (NCCN) criteria, so treatment was indicated; cancer would not have been detected in 74 (71.8%) of these participants according to the prostate cancer diagnostic pathway currently used in the United Kingdom (high PSA level and positive MRI results). In addition, 40 of the participants with cancer (21.4%) had disease classified as unfavorable intermediate risk or as high or very high risk according to NCCN criteria.CONCLUSIONSIn a prostate cancer screening program involving participants in the top decile of risk as determined by a polygenic risk score, the percentage found to have clinically significant disease was higher than the percentage that would have been identified with the use of PSA or MRI. (Funded by the European Research Council Seventh Framework Program and others; BARCODE1 ClinicalTrials.gov number, NCT03857477.).","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"218 1","pages":"1406-1417"},"PeriodicalIF":158.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143822496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jiwon Oh, Douglas L Arnold, Bruce A C Cree, Carolina Ionete, Ho Jin Kim, Maria Pia Sormani, Sana Syed, Yixin Chen, Christina R Maxwell, Patrick Benoit, Timothy J Turner, Erik Wallstroem, Heinz Wiendl
{"title":"Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.","authors":"Jiwon Oh, Douglas L Arnold, Bruce A C Cree, Carolina Ionete, Ho Jin Kim, Maria Pia Sormani, Sana Syed, Yixin Chen, Christina R Maxwell, Patrick Benoit, Timothy J Turner, Erik Wallstroem, Heinz Wiendl","doi":"10.1056/NEJMoa2415985","DOIUrl":"https://doi.org/10.1056/NEJMoa2415985","url":null,"abstract":"<p><strong>Background: </strong>Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton's tyrosine kinase inhibitor that modulates peripheral inflammation and persistent immune activation within the central nervous system, including disease-associated microglia and B cells. More data are needed on its efficacy and safety in treating relapsing multiple sclerosis.</p><p><strong>Methods: </strong>In two phase 3, double-blind, double-dummy, event-driven trials (GEMINI 1 and GEMINI 2), participants with relapsing multiple sclerosis were randomly assigned in a 1:1 ratio to receive tolebrutinib (60 mg once daily) or teriflunomide (14 mg once daily), each with matching placebo. The primary end point was the annualized relapse rate. The key secondary end point was confirmed worsening of disability that was sustained for at least 6 months, which was assessed in a time-to-event analysis that was pooled across trials.</p><p><strong>Results: </strong>A total of 974 participants were enrolled in GEMINI 1, and 899 were enrolled in GEMINI 2. The median follow-up was 139 weeks. The annualized relapse rate in the tolebrutinib and teriflunomide groups was 0.13 and 0.12, respectively, in GEMINI 1 (rate ratio, 1.06; 95% confidence interval [CI], 0.81 to 1.39; P = 0.67) and 0.11 and 0.11, respectively, in GEMINI 2 (rate ratio, 1.00; 95% CI, 0.75 to 1.32; P = 0.98). The pooled percentage of participants with confirmed disability worsening sustained for at least 6 months was 8.3% with tolebrutinib and 11.3% with teriflunomide (hazard ratio, 0.71; 95% CI, 0.53 to 0.95; no formal hypothesis testing was conducted owing to the prespecified hierarchical testing plan, and the width of the confidence interval is not adjusted for multiple testing). The percentage of participants who had adverse events was similar in the two treatment groups, although the percentage with minor bleeding was higher in the tolebrutinib group than in the teriflunomide group (petechiae occurred in 4.5% vs. 0.3%, and heavy menses in 2.6% vs. 1.0%).</p><p><strong>Conclusions: </strong>Tolebrutinib was not superior to teriflunomide in decreasing annualized relapse rates among participants with relapsing multiple sclerosis. (Funded by Sanofi; GEMINI 1 and GEMINI 2 ClinicalTrials.gov numbers, NCT04410978 and NCT04410991, respectively.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Richard J Nowak, Michael Benatar, Emma Ciafaloni, James F Howard, M Isabel Leite, Kimiaki Utsugisawa, John Vissing, Mikhail Rojavin, Qing Li, Fengming Tang, Yanping Wu, Nishi Rampal, Sue Cheng
{"title":"A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.","authors":"Richard J Nowak, Michael Benatar, Emma Ciafaloni, James F Howard, M Isabel Leite, Kimiaki Utsugisawa, John Vissing, Mikhail Rojavin, Qing Li, Fengming Tang, Yanping Wu, Nishi Rampal, Sue Cheng","doi":"10.1056/NEJMoa2501561","DOIUrl":"https://doi.org/10.1056/NEJMoa2501561","url":null,"abstract":"<p><strong>Background: </strong>Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to disease pathogenesis.</p><p><strong>Methods: </strong>In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled participants with myasthenia gravis who had anti-acetylcholine receptor antibodies or anti-muscle-specific kinase antibodies. Participants were randomly assigned, in a 1:1 ratio, to receive intravenous inebilizumab (300 mg administered on days 1 and 15 for all, and additionally on day 183 for participants who were acetylcholine receptor antibody-positive) or matching placebo for 52 weeks (in participants who were acetylcholine receptor antibody-positive) or 26 weeks (in those who were muscle-specific kinase antibody-positive). Glucocorticoid therapy was tapered, starting at week 4, to a target of 5 mg per day by week 24. The primary end point was the change from baseline in the score on the Myasthenia Gravis Activities of Daily Living scale (MG-ADL; scores range from 0 to 24, with higher scores indicating greater disease activity) at week 26 in the combined acetylcholine receptor antibody-positive and muscle-specific kinase antibody-positive trial populations. A key secondary end point was the change from baseline in the score on the Quantitative Myasthenia Gravis scale (QMG; scores range from 0 to 39, with higher scores indicating greater disease activity) at week 26 in the combined population. Safety was assessed.</p><p><strong>Results: </strong>A total of 238 participants underwent randomization (119 per group). Participants who received inebilizumab had a greater reduction in the MG-ADL score than those who received placebo (least-squares mean change, -4.2 vs. -2.2; adjusted difference, -1.9; 95% confidence interval [CI], -2.9 to -1.0; P<0.001) at week 26. Participants who received inebilizumab had a greater reduction in the QMG score than those who received placebo (least-squares mean change, -4.8 vs. -2.3; adjusted difference, -2.5; 95% CI, -3.8 to -1.2; P<0.001). The most common adverse events with inebilizumab were headache, cough, nasopharyngitis, infusion-related reactions, and urinary tract infections. Inebilizumab was not associated with a higher incidence of serious adverse events.</p><p><strong>Conclusions: </strong>In participants with acetylcholine receptor antibody-positive or muscle-specific kinase antibody-positive generalized myasthenia gravis, inebilizumab improved function and reduced disease severity. (Funded by Amgen; MINT ClinicalTrial.gov number, NCT04524273.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Robert J Fox, Amit Bar-Or, Anthony Traboulsee, Celia Oreja-Guevara, Gavin Giovannoni, Patrick Vermersch, Sana Syed, Ye Li, Wendy S Vargas, Timothy J Turner, Erik Wallstroem, Daniel S Reich
{"title":"Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.","authors":"Robert J Fox, Amit Bar-Or, Anthony Traboulsee, Celia Oreja-Guevara, Gavin Giovannoni, Patrick Vermersch, Sana Syed, Ye Li, Wendy S Vargas, Timothy J Turner, Erik Wallstroem, Daniel S Reich","doi":"10.1056/NEJMoa2415988","DOIUrl":"https://doi.org/10.1056/NEJMoa2415988","url":null,"abstract":"<p><strong>Background: </strong>Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclerosis have limited effects on disability accrual unrelated to relapses, which is thought to be partially caused by chronic, nonresolving neuroinflammation within the central nervous system. Tolebrutinib is an oral, brain-penetrant Bruton's tyrosine kinase inhibitor that targets myeloid cells (including microglia) and B cells in both the periphery and central nervous system. There are no approved treatments for nonrelapsing secondary progressive multiple sclerosis.</p><p><strong>Methods: </strong>In a phase 3, double-blind, placebo-controlled, event-driven trial, we randomly assigned participants with nonrelapsing secondary progressive multiple sclerosis, in a 2:1 ratio, to receive tolebrutinib (60 mg once daily) or matching placebo. The primary end point was confirmed disability progression that was sustained for at least 6 months, assessed in a time-to-event analysis.</p><p><strong>Results: </strong>A total of 1131 participants underwent randomization: 754 were assigned to receive tolebrutinib and 377 to receive placebo. The median follow-up was 133 weeks. A smaller percentage of participants in the tolebrutinib group than in the placebo group had confirmed disability progression sustained for at least 6 months (22.6% vs. 30.7%; hazard ratio, 0.69; 95% confidence interval, 0.55 to 0.88; P = 0.003). Serious adverse events occurred in 15.0% of the participants in the tolebrutinib group and in 10.4% of those in the placebo group. A total of 4.0% of the participants in the tolebrutinib group and 1.6% of those in the placebo group had increases in alanine aminotransferase levels to more than 3 times the upper limit of the normal range.</p><p><strong>Conclusions: </strong>In participants with nonrelapsing secondary progressive multiple sclerosis, the risk of disability progression was lower among those who received treatment with tolebrutinib than among those who received placebo. (Funded by Sanofi; HERCULES ClinicalTrials.gov number, NCT04411641.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Addressing Socioeconomic Barriers to Residency Choice.","authors":"Debra F Weinstein, Elena Olson, John Patrick T Co","doi":"10.1056/NEJMp2411273","DOIUrl":"https://doi.org/10.1056/NEJMp2411273","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Harleen Marwah, Mark McShane, Paul Devine Bottone, Noreena Sondhi Lewis
{"title":"Advancing Health Equity in the Climate Crisis - A Climate Justice Curriculum for Resident Physicians.","authors":"Harleen Marwah, Mark McShane, Paul Devine Bottone, Noreena Sondhi Lewis","doi":"10.1056/NEJMp2414715","DOIUrl":"https://doi.org/10.1056/NEJMp2414715","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ensuring Inclusive, Affirming Care for LGBTQ+ Patients - Scaling Up Cultural Competency Training.","authors":"Jay M Behel, Sally Lemke, Sanjeev Singh","doi":"10.1056/NEJMp2500381","DOIUrl":"https://doi.org/10.1056/NEJMp2500381","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}